Fidelity Investments’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $344K | Buy |
27,272
+22,960
| +532% | +$308K | ﹤0.01% | 3262 |
|
|
2025
Q4 | $68K | Buy |
4,312
+2,527
| +142% | +$32.1K | ﹤0.01% | 3949 |
|
|
2025
Q3 | $21.4K | Sell |
1,785
-6
| -0.3% | -$48 | ﹤0.01% | 4329 |
|
|
2025
Q2 | $13.5K | Sell |
1,791
-4,483
| -71% | -$27K | ﹤0.01% | 4433 |
|
|
2025
Q1 | $34.6K | Sell |
6,274
-71,310
| -92% | -$440K | ﹤0.01% | 4018 |
|
|
2024
Q4 | $446K | Buy |
77,584
+28,283
| +57% | +$271K | ﹤0.01% | 2973 |
|
|
2024
Q3 | $511K | Buy |
49,301
+7,839
| +19% | +$103K | ﹤0.01% | 2846 |
|
|
2024
Q2 | $538K | Buy |
41,462
+2,041
| +5% | +$27.6K | ﹤0.01% | 2710 |
|
|
2024
Q1 | $688K | Buy |
39,421
+8,756
| +29% | +$116K | ﹤0.01% | 2618 |
|
|
2023
Q4 | $289K | Sell |
30,665
-4,194
| -12% | -$39.1K | ﹤0.01% | 2838 |
|
|
2023
Q3 | $389K | Sell |
34,859
-105,399
| -75% | -$1.7M | ﹤0.01% | 2699 |
|
|
2023
Q2 | $3M | Buy |
140,258
+20,157
| +17% | +$594K | ﹤0.01% | 2208 |
|
|
2023
Q1 | $4.86M | Sell |
120,101
-144,642
| -55% | -$6.91M | ﹤0.01% | 2097 |
|
|
2022
Q4 | $12.3M | Sell |
264,743
-45,952
| -15% | -$2.09M | ﹤0.01% | 1812 |
|
|
2022
Q3 | $16.1M | Sell |
310,695
-39,638
| -11% | -$2.32M | ﹤0.01% | 1682 |
|
|
2022
Q2 | $16.6M | Buy |
350,333
+108,161
| +45% | +$5.87M | ﹤0.01% | 1727 |
|
|
2022
Q1 | $17.2M | Buy |
242,172
+242,160
| +2,018,000% | +$15.8M | ﹤0.01% | 1852 |
|
|
2021
Q4 | $1K | Hold |
12
| – | – | ﹤0.01% | 4125 |
|
|
2021
Q3 | $1K | Hold |
12
| – | – | ﹤0.01% | 4126 |
|
|
2021
Q2 | $1K | Buy |
+12
| New | +$588 | ﹤0.01% | 4022 |
|
|
2020
Q3 | – | Sell |
-54
| Closed | -$3K | – | 3754 |
|
|
2020
Q2 | $3K | Sell |
54
-12,141
| -100% | -$628K | ﹤0.01% | 3310 |
|
|
2020
Q1 | $627K | Sell |
12,195
-28,100
| -70% | -$1.5M | ﹤0.01% | 2401 |
|
|
2019
Q4 | $2.49M | Sell |
40,295
-39,500
| -50% | -$2.45M | ﹤0.01% | 2202 |
|
|
2019
Q3 | $4.79M | Sell |
79,795
-73,600
| -48% | -$5.47M | ﹤0.01% | 2070 |
|
|
2019
Q2 | $12.9M | Sell |
153,395
-86,800
| -36% | -$7.81M | ﹤0.01% | 1794 |
|
|
2019
Q1 | $22.9M | Buy |
240,195
+39,200
| +20% | +$3.52M | ﹤0.01% | 1549 |
|
|
2018
Q4 | $14.2M | Sell |
200,995
-88,025
| -30% | -$6.75M | ﹤0.01% | 1681 |
|
|
2018
Q3 | $24.7M | Sell |
289,020
-54,072
| -16% | -$5.42M | ﹤0.01% | 1594 |
|
|
2018
Q2 | $39.8M | Hold |
343,092
| – | – | ﹤0.01% | 1397 |
|
|
2018
Q1 | $27.8M | Buy |
343,092
+51,777
| +18% | +$3.99M | ﹤0.01% | 1570 |
|
|
2017
Q4 | $17.1M | Buy |
291,315
+9,500
| +3% | +$476K | ﹤0.01% | 1781 |
|
|
2017
Q3 | $13.2M | Buy |
281,815
+5,000
| +2% | +$201K | ﹤0.01% | 1847 |
|
|
2017
Q2 | $9.96M | Sell |
276,815
-10,000
| -3% | -$320K | ﹤0.01% | 1945 |
|
|
2017
Q1 | $8.83M | Sell |
286,815
-105,000
| -27% | -$3.27M | ﹤0.01% | 2009 |
|
|
2016
Q4 | $13.1M | Sell |
391,815
-20,000
| -5% | -$573K | ﹤0.01% | 1864 |
|
|
2016
Q3 | $11M | Sell |
411,815
-288,838
| -41% | -$6.71M | ﹤0.01% | 1950 |
|
|
2016
Q2 | $15.4M | Buy |
700,653
+51,538
| +8% | +$1.35M | ﹤0.01% | 1786 |
|
|
2016
Q1 | $19.1M | Sell |
649,115
-89,700
| -12% | -$2.5M | ﹤0.01% | 1682 |
|
|
2015
Q4 | $24.4M | Sell |
738,815
-214,173
| -22% | -$6.98M | ﹤0.01% | 1591 |
|
|
2015
Q3 | $34.4M | Hold |
952,988
| – | – | ﹤0.01% | 1413 |
|
|
2015
Q2 | $42.9M | Sell |
952,988
-406,447
| -30% | -$15.8M | 0.01% | 1404 |
|
|
2015
Q1 | $41.6M | Sell |
1,359,435
-775,823
| -36% | -$30.2M | 0.01% | 1415 |
|
|
2014
Q4 | $109M | Buy |
2,135,258
+126,750
| +6% | +$5.67M | 0.01% | 970 |
|
|
2014
Q3 | $79.5M | Buy |
2,008,508
+5,300
| +0.3% | +$211K | 0.01% | 1076 |
|
|
2014
Q2 | $86.3M | Sell |
2,003,208
-464,500
| -19% | -$17.7M | 0.01% | 1083 |
|
|
2014
Q1 | $98.7M | Buy |
2,467,708
+1,169,232
| +90% | +$42.5M | 0.01% | 995 |
|
|
2013
Q4 | $35.4M | Buy |
+1,298,476
| New | +$31.5M | 0.01% | 1479 |
|
Other funds holding ENTA
FCM
KAM
DTC
VCM
VPM
SSC
Fidelity Investments's ENTA Position: Q1 2026 in Review
Fidelity Investments increased its Enanta Pharmaceuticals (ENTA) stake by 532% in Q1 2026, buying an estimated $308K and bringing the position to 27,272 shares worth $344K. The position accounts for ﹤0.01% of the portfolio, ranked #3262.
Fidelity Investments first reported a position in ENTA in Q4 2013 and has held it in 47 quarters since. The position peaked at $109M in Q4 2014. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.
- Fidelity Investments held 27,272 shares of Enanta Pharmaceuticals worth $344K as of Q1 2026.
- Fidelity Investments bought 22,960 Enanta Pharmaceuticals shares in Q1 2026, an estimated $308K.
- Enanta Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #3262 holding.
- Fidelity Investments first reported a position in Enanta Pharmaceuticals in Q4 2013 and has held it in 47 quarters since.
- Fidelity Investments's Enanta Pharmaceuticals position peaked at $109M in Q4 2014.
- 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.